Genaera Discontinues Phase II Studies Of Lomucin And Squalamine
This article was originally published in The Pink Sheet Daily
Executive Summary
Termination of the studies reflects Genaera’s decision to focus on core assets trodusquemine for obesity and anti-IL-9 program for asthma.